AusperBio Closes $120M Series C for AHB-137 Hepatitis B Program
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial...
MBX Biosciences Doses First Patient in Phase 3 Canvuparatide Trial for Hypoparathyroidism
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal study...
Genentech, DualityBio Partner on Next-Generation ADC Payloads
Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in cancer patients.
When the Sponsor’s IT Goes Down, Your Trial Goes With It
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...
TALENTOP Proved Conversion Surgery Works in Advanced HCC. Now Comes the Harder Question.
TALENTOP's phase 3 data shows liver resection after atezo-bev nearly doubles time to treatment failure in advanced HCC. The...
SPY072 Misses Primary Endpoint in Rheumatoid Arthritis Study
SPY072 missed its primary endpoint in a rheumatoid arthritis study, narrowing the drug candidate's development path outside inflammatory bowel...
Generate Biomedicines’ GB-0895 Phase 1 Data Released Early Ahead of ERS Presentation
Generate Biomedicines' GB-0895 Phase 1 data released early, showing results in mild-to-moderate asthma and COPD ahead of ERS presentation.
Ivonescimab Beats Durvalumab in Phase III Biliary Tract Cancer Trial
Ivonescimab beats durvalumab in Phase III HARMONi-GI1 trial for biliary tract cancer, meeting primary overall survival endpoint as first-line...
AbbVie Seeks EMA Approval for SKYRIZI Subcutaneous Induction in Crohn’s Disease
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
Tezspire Hits Both Primary Endpoints in Phase 3 Eosinophilic Esophagitis Trial
Tezspire hits both primary endpoints in Phase 3 eosinophilic esophagitis trial, addressing histologic remission and dysphagia symptom relief through...